InnotiveDx gets £1m grant to advance UTI diagnostics system
Esme Needham | November 27, 2025 | News story | Research and Development | Diagnostics, InnotiveDx, Urology
InnotiveDx has announced that it has received a £1m grant from Pathways to Antimicrobial Clinical Efficacy (PACE) to advance the development of its urinary tract infection (UTI) diagnostics system and InnotiveUTI test.
UTIs affect hundreds of millions of people per year globally and result in more than 20% of all antibiotic prescriptions. This exacerbates antimicrobial resistance (AMR), costing healthcare systems billions of dollars worldwide. These figures highlight an urgent need to find a more reliable way to correctly diagnose UTIs.
InnotiveDx’s UTI diagnostic technology has been demonstrated to provide accurate bacterial ID and antimicrobial susceptibility test results in under 60 minutes, with a benchtop assay accuracy of over 96% in blinded evaluations.
The new £1m grant will allow InnotiveDx to fully assess the accuracy and consistency of the automated prototypes it has created from its underlying diagnostic technology. The company will use thousands of clinical specimens to assess the prototypes, before transitioning to real-world clinical studies.
InnotiveDx is an in-vitro diagnostics company specialising in the diagnosis and treatment of UTIs. James Mainwaring, chief commercial and operating officer at InnotiveDx, said of the grant: “it is a tremendous validation of our technology, vision and all the hard work our team has put in since spinout. AMR is one of the most pressing challenges humanity faces and we are looking forward to tackling this problem with like-minded individuals from PACE.”
PACE is one of the UK’s biggest public-private initiatives targeting early-stage antimicrobial drug and diagnostic discovery. Dr Beverley Isherwood, PACE programme director, said: “PACE will support InnotiveDx advance InnotiveUTI using a collaborative approach, helping them generate the essential validation data required to position their project for onward development, funding and investment.”
Related Content
University of Birmingham scientists develop new MRI contrast agent
Researchers at the University of Birmingham, UK, have developed a new class of magnetic resonance …
Inbiome’s rapid diagnostic platform approved for EU use, cuts infection identification time to just five hours
Dutch diagnostics firm Inbiome has received In Vitro Diagnostic Regulation (IVDR) certification from the EU …
NICE recommends digital tech for ADHD diagnosis in children and young people
The National Institute for Health and Care Excellence (NICE) has announced that its diagnostics advisory …
